Highly active antiretroviral therapies may be cardioprotective in HIV-infected children, teens

Long-term use of highly active antiretroviral therapies (HAART) does not appear to be associated with impaired heart function in children and adolescents in a study that sought to determine the cardiac effects of prolonged exposure to HAART on children infected with the human immunodeficiency virus (HIV), according to a report published Online First by JAMA Pediatrics.

Prior to contemporary (ARTs), children infected with HIV were more likely to have heart failure.

Steven E. Lipshultz, M.D., of the University of Miami Leonard M. Miller School of Medicine, Florida, and colleagues used statistical models to compare echocardiographic measures in the National Institutes of Health-funded Pediatric HIV/AIDS 's Adolescent Master Protocol (AMP).

The study included 14 pediatric HIV clinics in the United States. The participants were 325 perinatally HIV-infected children receiving HAART; 189 HIV-exposed but uninfected children; and 70 HIV-infected (mostly HAART-unexposed) historical pediatric controls patients from the National Institutes of Health-funded Pulmonary and Cardiovascular Complications of Vertically Transmitted (P2C2-HIV) Study.

"Our results indicate that the current use of combination ART, usually HAART, appears to be cardioprotective in HIV-infected children and adolescents. This finding is even more relevant in the developing world where the prevalence of HIV disease in children is much higher," the study notes.

Scores for left ventricular (LV) fractional shortening (a measure of cardiac function) were significantly lower among HIV-infected children from the P2C2-HIV Study than among the AMP HIV-infected group or the 189 AMP HIV-exposed but uninfected controls, the study results indicate. The results also show that for HIV-infected children, a lower nadir CD4 percentage and a higher current viral load were associated with significantly lower cardiac function.

"This study suggests that highly active ART (HAART) does not appear to impair ," the study concludes.

More information: JAMA Pediatr. Published online April 22, 2013. doi:10.1001/jamapediatrics.2013.1206

add to favorites email to friend print save as pdf

Related Stories

Revaccination could benefit HIV-infected children

Sep 01, 2010

HIV-infected children receiving highly active antiretroviral therapy (HAART) may require revaccination to maintain immunity against preventable diseases. There remains no standard or official recommendation on revaccination ...

HIV treatment use increases in the US

Sep 03, 2012

Between 2000 and 2008, the proportion of HIV-infected patients in the U.S. receiving effective treatment known as highly active antiretroviral therapy (HAART) increased, and HIV-infected patients appeared to be less infectious ...

Recommended for you

Survival of very premature infants is improving in France

Jan 29, 2015

Since 2011, nearly 7,000 premature infants have been enrolled in the Inserm EPIPAGE 2 study. This study is aimed at assessing the survival of infants born between 22 and 34 weeks' gestation, and their subsequent ...

Donors pledge $7.5 bn to extend child vaccine drive

Jan 27, 2015

Countries and private donors have pledged $7.5 billion (6.6 billion euros) to help immunise 300 million more children in developing countries over the next five years, a major vaccine alliance announced Tuesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.